Prognostic Molecular Markers Determined by Using Gene Expression Profiling in Patients With Myelodysplastic Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Myelodysplastic Syndrome
- Sponsor
- Samsung Medical Center
- Enrollment
- 58
- Locations
- 1
- Primary Endpoint
- overall survival
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
In the era of hypomethylating agent in MDS treatment, the investigators aimed to investigate the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.
Detailed Description
A number of studies have tried to investigate clinical impact of mutations in spliceosomal machinery genes in MDS but they failed to demonstrate a consistent prognostic relevance. Moreover, the clinical impact of these mutations on the outcomes of hypomethylating agent treatment in MDS has never been explored yet. The investigators investigated the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.
Investigators
Jun Ho Jang
Jun Ho Jang
Samsung Medical Center
Eligibility Criteria
Inclusion Criteria
- •de novo MDS patients were included in the study who had received 1st line decitabine treatment and had adequate genomic DNA from pretreated bone marrow samples
Exclusion Criteria
- •therapy-related MDS
Outcomes
Primary Outcomes
overall survival
Time Frame: Two years